ORIC Pharmaceuticals (ORIC) News Today $6.35 +0.40 (+6.72%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.60 +0.25 (+3.94%) As of 05/23/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Frazier Life Sciences Management L.P. Sells 254,617 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Frazier Life Sciences Management L.P. trimmed its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 6.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,888,238 shares of the company's stock after selMay 23 at 7:51 AM | marketbeat.comCantor Fitzgerald maintains Overweight on ORIC sharesMay 22 at 1:36 AM | uk.investing.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by BrokeragesShares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have earned a consensus rating of "Buy" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price objectMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Acquires 144,817 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Sphera Funds Management LTD. lifted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 112.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 273,213 shares of the companyMay 18, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by NEA Management Company LLCNEA Management Company LLC raised its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 4.4% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,566,081 shares of the company's stock after buying an additional 66,081 shares during the qMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 103,237 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Dimensional Fund Advisors LP increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 717,188 shares of the compMay 13, 2025 | marketbeat.comBalyasny Asset Management L.P. Purchases 424,194 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Balyasny Asset Management L.P. grew its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 37.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,555,260 shares of the company's stock after purchasing anMay 11, 2025 | marketbeat.comQ2 EPS Forecast for ORIC Pharmaceuticals Raised by AnalystORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Equities researchers at Wedbush upped their Q2 2025 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Monday, May 5th. Wedbush analyst D. Nierengarten now forecasts that the compMay 10, 2025 | marketbeat.comOppenheimer Cuts ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target to $12.00Oppenheimer cut their target price on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a research note on Tuesday.May 8, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)Cantor Fitzgerald reiterated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday.May 8, 2025 | marketbeat.comORIC Pharmaceuticals Outlines Clinical Development Plans and Financial Updates for ORIC-944 and ORIC-114May 7, 2025 | nasdaq.comORIC Pharmaceuticals (NASDAQ:ORIC) Releases Earnings Results, Beats Estimates By $0.10 EPSORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.10.May 7, 2025 | marketbeat.comORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Monday.May 7, 2025 | marketbeat.comORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational UpdatesMay 5, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Schonfeld Strategic Advisors LLC acquired a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 724,319 shares of the company's stMay 5, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 180,140 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Price T Rowe Associates Inc. MD lifted its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 16.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,295,025 shares of the company's stock after purchasing an additional 180,14May 5, 2025 | marketbeat.comBoxer Capital Management LLC Purchases Shares of 1,732,571 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Boxer Capital Management LLC purchased a new position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,732,571 shares of the compaMay 4, 2025 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comAdage Capital Partners GP L.L.C. Has $4.04 Million Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Adage Capital Partners GP L.L.C. reduced its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 500,000 shares of the company's sMay 2, 2025 | marketbeat.comORIC Pharmaceuticals (ORIC) to Release Earnings on MondayORIC Pharmaceuticals (NASDAQ:ORIC) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-oric-pharmaceuticals-inc-stock/)April 30, 2025 | marketbeat.comORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual MeetingApril 28, 2025 | globenewswire.comNatixis Acquires New Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Natixis bought a new position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 79,900 shares of the company's stock, valued at approximately $645,000. Natixis owned abouApril 26, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Silverarc Capital Management LLCSilverarc Capital Management LLC grew its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,178,300 shares of the companyApril 24, 2025 | marketbeat.comDiadema Partners LP Purchases Shares of 214,291 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Diadema Partners LP acquired a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 214,291 shares of the company's stock, valuApril 24, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Buy" from AnalystsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has received a consensus recommendation of "Buy" from the nine research firms that are covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year target price among broApril 24, 2025 | marketbeat.comORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study PlansApril 22, 2025 | seekingalpha.comORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch BiotechApril 22, 2025 | seekingalpha.comOric Pharmaceuticals Inc.April 17, 2025 | barrons.comIs ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | msn.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comNEOS Investment Management LLC Purchases Shares of 45,476 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)NEOS Investment Management LLC acquired a new position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 45,476 shares of the company's stock,April 2, 2025 | marketbeat.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMarch 31, 2025 | globenewswire.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by AnalystsShares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given an average rating of "Buy" by the nine research firms that are currently covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month pMarch 29, 2025 | marketbeat.comOppenheimer Remains a Buy on Zentalis Pharmaceuticals (ZNTL)March 27, 2025 | markets.businessinsider.comORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 4.9% - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% - What's Next?March 22, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from WedbushWedbush reiterated an "outperform" rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday.March 21, 2025 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fulgent Genetics (FLGT), Alignment Healthcare (ALHC) and Syndax Pharmaceuticals (SNDX)March 4, 2025 | markets.businessinsider.comORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on MondayORIC Pharmaceuticals (NASDAQ:ORIC) will be releasing earnings before the market opens on Monday, March 10.March 3, 2025 | marketbeat.comWedbush Lifts Earnings Estimates for ORIC PharmaceuticalsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Wedbush lifted their Q1 2025 earnings estimates for ORIC Pharmaceuticals in a research note issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.50) per share for the quarter, up fromMarch 1, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 13.9% Higher on Analyst UpgradeORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst UpgradeFebruary 27, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from GuggenheimGuggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday.February 26, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. raised their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday.February 26, 2025 | marketbeat.comOric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114February 26, 2025 | markets.businessinsider.comOric Pharmaceuticals (ORIC) Gets a Buy from OppenheimerFebruary 26, 2025 | markets.businessinsider.comORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate MilestonesFebruary 25, 2025 | globenewswire.comHC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Friday.February 22, 2025 | marketbeat.comWedbush Expects Reduced Earnings for ORIC PharmaceuticalsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings per share estimates for shares of ORIC Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now forecasts thFebruary 22, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Earnings BeatORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Strong EarningsFebruary 20, 2025 | marketbeat.com Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼1.010.75▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼43▲ORIC Articles Average Week Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Structure Therapeutics News Today Janux Therapeutics News Today Evotec News Today ARS Pharmaceuticals News Today Adaptive Biotechnologies News Today Vera Therapeutics News Today Dyne Therapeutics News Today ANI Pharmaceuticals News Today Qilian International Holding Group News Today Ocular Therapeutix News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
